AU2002317482B2 - 5-halo-tryptamine derivatives used as ligands of the 5-HT6 and/or 5-HT7 serotonin receptors - Google Patents

5-halo-tryptamine derivatives used as ligands of the 5-HT6 and/or 5-HT7 serotonin receptors Download PDF

Info

Publication number
AU2002317482B2
AU2002317482B2 AU2002317482A AU2002317482A AU2002317482B2 AU 2002317482 B2 AU2002317482 B2 AU 2002317482B2 AU 2002317482 A AU2002317482 A AU 2002317482A AU 2002317482 A AU2002317482 A AU 2002317482A AU 2002317482 B2 AU2002317482 B2 AU 2002317482B2
Authority
AU
Australia
Prior art keywords
use according
disease
compounds
medicaments
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002317482A
Other languages
English (en)
Other versions
AU2002317482A1 (en
Inventor
Maria Assunta Di Cesare
Patrizia Minetti
Gilberto Spadoni
Giorgio Tarzia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of AU2002317482A1 publication Critical patent/AU2002317482A1/en
Application granted granted Critical
Publication of AU2002317482B2 publication Critical patent/AU2002317482B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
AU2002317482A 2001-06-21 2002-06-17 5-halo-tryptamine derivatives used as ligands of the 5-HT6 and/or 5-HT7 serotonin receptors Ceased AU2002317482B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITRM01A000356 2001-06-21
IT2001RM000356A ITRM20010356A1 (it) 2001-06-21 2001-06-21 "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.
PCT/IT2002/000398 WO2003000252A1 (en) 2001-06-21 2002-06-17 5-halo-tryptamine derivatives used as ligands of the 5-ht6 and/or 5-ht7 serotonin receptors

Publications (2)

Publication Number Publication Date
AU2002317482A1 AU2002317482A1 (en) 2003-06-19
AU2002317482B2 true AU2002317482B2 (en) 2007-08-16

Family

ID=11455609

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002317482A Ceased AU2002317482B2 (en) 2001-06-21 2002-06-17 5-halo-tryptamine derivatives used as ligands of the 5-HT6 and/or 5-HT7 serotonin receptors

Country Status (21)

Country Link
US (1) US7098233B2 (enExample)
EP (1) EP1404317B1 (enExample)
JP (2) JP4683839B2 (enExample)
KR (1) KR100885308B1 (enExample)
CN (1) CN100482223C (enExample)
AT (1) ATE416767T1 (enExample)
AU (1) AU2002317482B2 (enExample)
BR (1) BR0210538A (enExample)
CA (1) CA2455296C (enExample)
CY (1) CY1108879T1 (enExample)
CZ (1) CZ20033314A3 (enExample)
DE (1) DE60230270D1 (enExample)
DK (1) DK1404317T3 (enExample)
ES (1) ES2319107T3 (enExample)
HU (1) HUP0400250A3 (enExample)
IT (1) ITRM20010356A1 (enExample)
MX (1) MXPA03011510A (enExample)
PL (1) PL367618A1 (enExample)
PT (1) PT1404317E (enExample)
SK (1) SK287828B6 (enExample)
WO (1) WO2003000252A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039127A1 (es) * 2002-03-27 2005-02-09 Glaxo Group Ltd Compuesto de quinolina, procedimiento para su preparacion, composicion farmaceutica que lo comprende y uso del mismo para la fabricacion de un medicamento
NZ544331A (en) 2003-07-22 2010-03-26 Arena Pharm Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
US8086315B2 (en) 2004-02-12 2011-12-27 Asap Medical, Inc. Cardiac stimulation apparatus and method for the control of hypertension
CA2557158A1 (en) * 2004-02-20 2005-09-01 Astellas Pharma Inc. Prophylactic antimigraine agents
US20080171788A1 (en) * 2005-02-08 2008-07-17 Shinobu Akuzawa Medicament For Irritable Bowel Syndrome
EP1923387B1 (en) 2005-08-08 2011-10-19 Astellas Pharma Inc. Acylguanidine derivative or salt thereof
WO2007046112A1 (en) * 2005-10-19 2007-04-26 Suven Life Sciences Inc. Arylthioether tryptamine derivatives as functional 5-ht6 ligands
WO2007097276A1 (ja) * 2006-02-20 2007-08-30 Astellas Pharma Inc. ピロール誘導体またはその塩
EP2120950B1 (en) * 2007-03-21 2012-07-04 Glaxo Group Limited Use of quinoline derivatives in the treatment of pain
EP2209380A4 (en) * 2007-10-09 2011-09-14 Mark T Hamann METHOD OF USE OF COMPOSITIONS WITH ANTIDEPRESSIVE EFFICACY, MOOD EFFICACY AND OTHER NEUROLOGICAL EFFECTIVENESS AND COMPOSITIONS THEREOF
EP2254564A1 (en) 2007-12-12 2010-12-01 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
CA2842455A1 (en) * 2011-08-05 2013-02-14 Sucampo Ag Method for treating schizophrenia
CN102816103B (zh) * 2012-08-20 2014-05-07 冉瑞琼 硫化天冬氨酸修饰的退黑素衍生物及其应用
US9008769B2 (en) 2012-12-21 2015-04-14 Backbeat Medical, Inc. Methods and systems for lowering blood pressure through reduction of ventricle filling
US9370662B2 (en) 2013-12-19 2016-06-21 Backbeat Medical, Inc. Methods and systems for controlling blood pressure by controlling atrial pressure
CN104529865B (zh) * 2014-12-12 2017-02-01 广东东阳光药业有限公司 苄胺类衍生物及其在药物上的应用
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
CN108472285A (zh) 2015-07-15 2018-08-31 阿速万科学有限责任公司 用于预防和治疗与神经退行性疾病相关联的幻觉的二芳基和芳基杂芳基脲衍生物
US10342982B2 (en) 2015-09-11 2019-07-09 Backbeat Medical, Inc. Methods and systems for treating cardiac malfunction
US10485658B2 (en) 2016-04-22 2019-11-26 Backbeat Medical, Inc. Methods and systems for controlling blood pressure
CN108926565A (zh) * 2017-05-26 2018-12-04 中国科学院上海生命科学研究院 五羟色胺受体亚型6小分子激活剂及拮抗剂在防治阿尔茨海默症中的应用
EP3813810A4 (en) * 2018-06-21 2022-03-30 Robert John Petcavich METHODS OF INDUCING DENDRITICAL AND SYNAPTIC GENESIS IN CHRONIC NEURODEGENERATIVE DISEASES
GB201907871D0 (en) * 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
LT4084791T (lt) * 2020-02-18 2025-02-25 Gilgamesh Pharmaceuticals, Inc. Specifiniai triptaminai, skirti nuotaikos sutrikimams gydyti
IL297861A (en) 2020-05-08 2023-01-01 Psilera Inc Novel compositions of matter and pharmaceutical compositions
IL312785B2 (en) 2020-05-19 2026-06-01 Cybin Irl Ltd Deuterated tryptamine derivatives and methods of use
WO2021116503A2 (en) * 2020-06-02 2021-06-17 Small Pharma Ltd Deuterated compounds
WO2022061196A1 (en) * 2020-09-18 2022-03-24 Mydecine Innovations Group Inc. Novel formulations of psilocybin and psilocin compounds as serotonin agonists in combination with 3,4 methylenedioxymethamphetamine (mdma)
KR20240013170A (ko) 2021-05-25 2024-01-30 아타이 테라퓨틱스, 인크. 신규 n,n-디메틸트립타민 염 및 결정질 염 형태
IL309210A (en) 2021-06-09 2024-02-01 Atai Therapeutics Inc Parent drugs and conjugates of dimethyltryptamine
US20240343692A1 (en) * 2021-08-09 2024-10-17 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Selective psychedelic compounds
CA3238440A1 (en) * 2021-12-30 2023-07-06 Atai Therapeutics, Inc. Dimethyltryptamine analogues as nitric oxide delivery drugs
CN114573578B (zh) * 2022-02-16 2023-11-17 烟台宁远药业有限公司 一种烷基取代氮杂吲哚的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034242A1 (en) * 1998-12-11 2000-06-15 Virginia Commonwealth University Selective 5-ht6 receptor ligands

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2825734A (en) * 1955-04-11 1958-03-04 Upjohn Co Reduction of carbonylic radicals in indolyl-3 compounds
GB966562A (en) * 1961-04-06 1964-08-12 Parke Davis & Co Amine compounds and means of producing the same
FR2315277A1 (fr) * 1975-06-25 1977-01-21 Anvar Nouveaux derives pentacycliques, leur preparation et les compositions qui les contiennent
US4428877A (en) * 1978-07-12 1984-01-31 Richter Gedeon Vegyeszeti Gyar Rt. Cis-10-bromo-E-homoeburnanes
GB8531612D0 (en) * 1985-12-23 1986-02-05 Beecham Wuelfing Gmbh & Co Kg Compounds
US5300645A (en) * 1993-04-14 1994-04-05 Eli Lilly And Company Tetrahydro-pyrido-indole
FR2712591B1 (fr) * 1993-11-19 1996-02-09 Pf Medicament Nouvelles arylpipérazines dérivées d'indole, leur préparation et leur utilisation thérapeutique.
US5688807A (en) * 1994-03-11 1997-11-18 Eli Lilly And Company Method for treating 5HT2B receptor related conditions
US5504101A (en) * 1994-05-06 1996-04-02 Allelix Biopharmaceuticals, Inc. 5-HT-1D receptor ligands
WO1998000400A1 (en) * 1996-06-28 1998-01-08 Meiji Seika Kaisha, Ltd. Tetrahydrobenzindole compounds
US6100291A (en) * 1998-03-16 2000-08-08 Allelix Biopharmaceuticals Inc. Pyrrolidine-indole compounds having 5-HT6 affinity
US6251893B1 (en) * 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
US6403808B1 (en) * 1999-12-10 2002-06-11 Virginia Commonwealth University Selective 5-HT6 receptor ligands
EP1173432B9 (en) * 1999-04-21 2008-10-15 NPS Allelix Corp. Piperidine-indole compounds having 5-ht6 affinity
AU779832B2 (en) 1999-08-12 2005-02-10 Nps Pharmaceuticals, Inc. Azaindoles having serotonin receptor affinity
WO2004041781A1 (en) * 2002-11-07 2004-05-21 Suven Life Sciences Limited Preparation of 3-aminoalkyl-substituted indole derivatives from phenylhydrazines and aminoketones

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034242A1 (en) * 1998-12-11 2000-06-15 Virginia Commonwealth University Selective 5-ht6 receptor ligands

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Medicinal Chemistry Reseach (2000) 4(10) pp 230-42 *

Also Published As

Publication number Publication date
DE60230270D1 (de) 2009-01-22
PT1404317E (pt) 2009-02-23
BR0210538A (pt) 2004-06-22
CY1108879T1 (el) 2014-07-02
KR100885308B1 (ko) 2009-02-24
ITRM20010356A1 (it) 2002-12-23
ES2319107T3 (es) 2009-05-04
CZ20033314A3 (cs) 2004-08-18
DK1404317T3 (da) 2009-02-23
HUP0400250A2 (hu) 2004-08-30
JP2011016835A (ja) 2011-01-27
CA2455296C (en) 2010-08-17
WO2003000252A1 (en) 2003-01-03
JP4683839B2 (ja) 2011-05-18
MXPA03011510A (es) 2004-03-18
HK1068792A1 (zh) 2005-05-06
JP2004534816A (ja) 2004-11-18
ITRM20010356A0 (it) 2001-06-21
SK382004A3 (en) 2004-05-04
CA2455296A1 (en) 2003-01-03
SK287828B6 (sk) 2011-11-04
PL367618A1 (en) 2005-03-07
US7098233B2 (en) 2006-08-29
EP1404317A1 (en) 2004-04-07
KR20040032113A (ko) 2004-04-14
US20040235899A1 (en) 2004-11-25
CN1535146A (zh) 2004-10-06
ATE416767T1 (de) 2008-12-15
EP1404317B1 (en) 2008-12-10
CN100482223C (zh) 2009-04-29
HUP0400250A3 (en) 2008-03-28

Similar Documents

Publication Publication Date Title
CA2455296C (en) 5-halo-tryptamine derivatives used as ligands of the 5-ht6 and/or 5-ht7 serotonin receptors
AU2002317482A1 (en) 5-halo-tryptamine derivatives used as ligands of the 5-HT6 and/or 5-HT7 serotonin receptors
Thompson et al. Synthesis and pharmacological evaluation of a series of dibenzo [a, d] cycloalkenimines as N-methyl-D-aspartate antagonists
WO2005047286A1 (ja) スピロ複素環化合物
MXPA04011331A (es) 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de 5-hidroxitriptamina-6.
LV12792A (en) Formyl- or cyano- indole derivatives having dopaminergic activity
BR112013000783A2 (pt) derivados arilamídicos tendo propriedades antiandrogênicas
MXPA06001229A (es) Derivados de 1-sulfonilindol, su preparacion y su uso como ligandos de 5-ht6.
JP2017532377A (ja) インドリノン化合物及びその使用
AU2009330131A1 (en) Compounds and methods for the treatment of pain and other diseases
FR2930249A1 (fr) Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique.
JP5575663B2 (ja) 置換された２−アミノ−３−（スルホニル）ピラゾロ［１，５−ａ］ピリミジン−セロトニン５−ＨＴ６受容体アンタゴニスト、その調製のための方法及び使用
MXPA06005103A (es) Compuestos de sulfoniltetrahidro-3h-benzo(e)indol-8-amina como ligandos de 5-hidroxitriptamina-6.
CN109641877A (zh) 结合5-ht7血清素受体的经咪唑基取代的吲哚衍生物及其药物组合物
JP2009517453A (ja) Ｐｄｅ７阻害剤としてのスピロ環式キナゾリン誘導体
CN104870451B (zh) 二氢‑吡啶并噁嗪衍生物的固体形式
JP5690594B2 (ja) ３−（スルホニル）ピラゾロ［１，５−ａ］ピリミジン−セロトニン５−ＨＴ６受容体のアンタゴニスト、その調製の方法及び使用
WO2017183723A1 (ja) Ｋｃｎｑ２～５チャネル活性化剤
WO2010040315A1 (zh) 1-丁基-2-羟基芳烷哌嗪衍生物及作为抗抑郁剂的应用
JP2009545555A (ja) 置換インダニルスルホンアミド化合物、それらの調製、および薬剤としての使用
JPH08151366A (ja) １−ヒドロキシインドール誘導体
TW200819426A (en) Novel indane compounds
HK1068792B (en) 5-halo-tryptamine derivatives used as ligands of the 5-ht6 and/or 5-ht7 serotonin receptors
TW379220B (en) Pyrazolidine derivative, radical scavenger, brain--infarction depressant, and brain-edma depressant
TW200800888A (en) Substituted propylamine derivatives and methods of their use

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired